Evidence map›Paper›PMID 38247640›Full record

ArticleAntibiotics (Basel, Switzerland)2024

In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria-A Pilot Study in Bulgaria.

Rumyana Markovska, Petya Stankova, Temenuga Stoeva, Emma Keuleyan, Kalina Mihova, Lyudmila Boyanova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Emergence ofAntibiotics (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Rumyana MarkovskaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0003-1634-8768
Petya StankovaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, 1431 Sofia, Bulgaria.
Temenuga StoevaDepartment of Microbiology and Virology, University Multiprofile Hospital for Active Treatment (UMHAT) "Saint Marina", Medical University of Varna, 9002 Varna, Bulgaria.
Emma KeuleyanDepartment of Clinical Microbiology, Medical Institute-Ministry of the Interior, 1606 Sofia, Bulgaria.ORCID 0000-0003-2641-6453
Kalina MihovaMolecular Medicine Center, Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0001-5657-9443
Lyudmila BoyanovaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0001-9622-0873
Medical University of Sofia · BGMedical University of Varna · BGMinistry of Interior · BG

Funding

Medical University of Sofia 210/03.08.2023
6 · The paper itself

Abstract

To solve the problem with pan-drug resistant and extensively drug-resistant Gram-negative microbes, newly approved drugs such as ceftazidime/avibactam, cefiderocol, plazomicin, meropenem/vaborbactam, and eravacycline have been introduced in practice. The aim of the present study was to collect carbapenemase-producing clinical

Indexed as

carbapenemasesEnterobacteralesnovel antibiotics

Identifiers

PMID38247640
PMCPMC10812743
OpenAlexW4390877329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.